Bayers-new-symptomatic-chronic-heart-failure-treatment-Verquvo-vericiguat-approved-in-EU

Approved for adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy / Studied in a population with a high risk of cardiovascular death or heart failure hospitalization / The sGC-stimulator Verquvo provides a specific approach to managing chronic heart failure following a decompensation event
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news